ReviewHypertension research : official journal of the Japanese Society of Hypertension2020
Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19.
Review in Hypertension research : official journal of the Japanese Society of Hypertension, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 2 syntheses or guidelines pooled it, 177 citations in OpenAlex.
- Prevalence of hypertension and associated risks in hospitalized patients with COVID-19: a meta-analysis of meta-analyses with 1468 studies and 1,281,510 patients.Systematic reviews · 2022Pooled it
- Overexpression of angiotensin-converting enzyme 2 by renin-angiotensin system inhibitors. Truth or myth? A systematic review of animal studies.Hypertension research : official journal of the Japanese Society of Hypertension · 2021Pooled it
- Common surgical masks and unattended blood pressure changes in treated hypertensive patients.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Trial
- Digital therapeutics for essential hypertension using a smartphone application: A randomized, open-label, multicenter pilot study.Journal of clinical hypertension (Greenwich, Conn.) · 2021Trial
- The profound impact of COVID-19 on the control and care of diabetic patients: a comprehensive retrospective cohort study.BMC primary care · 2024Article
- Shadow left by COVID-19 pandemic on the future.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- The trends of antihypertensive drug prescription based on the Japanese national data throughout the COVID-19 pandemic period.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- National and Regional Trends in the Prevalence of Hypertension in South Korea Amid the Pandemic, 2009-2022: Nationwide Study of Over 3 Million Individuals.JMIR public health and surveillance · 2024Article
- Association between blood pressure and COVID-19 severity.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Knowledge, attitudes, and practices of chronic disease patients in Bojanala towards COVID-19.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2023Article
- Evolution of Cardiovascular Risk Factors in Post-COVID Patients.Journal of clinical medicine · 2023Article
- What impacts do the new ESH 2023 guidelines have on the management of hypertension in Japan?Hypertension research : official journal of the Japanese Society of Hypertension · 2023Article
- Peak home blood pressure as an earlier and strong novel risk factor for stroke: the practitioner-based nationwide J-HOP study extended.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Article
- Risk factors for COVID-19 infection and hospitalization, a population based case-control study from eastern Iran.IJID regions · 2023Article
- Topics 2023 in Hypertension Research leading to guidelines in Asia.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Article
- Reply to: Hypertension and severe COVID-19.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Article
- Health system adaptions to improve care for people living with non-communicable diseases during COVID-19 in low-middle income countries: A scoping review.Journal of global health · 2023Article
- Long COVID and hypertension-related disorders: a report from the Japanese Society of Hypertension Project Team on COVID-19.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Review
- Clinical determinants of oxygen saturation and length of hospitalisation of COVID-19 patients: A cross-sectional study in Indonesia.Enfermeria clinica · 2023Article
- Validation of a specialized evaluation system for COVID-19 in Japan: A retrospective, multicenter cohort study.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2023Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 13 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected more than seven million people worldwide, contributing to 0.4 million deaths as of June 2020. The fact that the virus uses angiotensin-converting enzyme (ACE)-2 as the cell entry receptor and that hypertension as well as cardiovascular disorders frequently coexist with COVID-19 have generated considerable discussion on the management of patients with hypertension. In addition, the COVID-19 pandemic necessitates the development of and adaptation to a "New Normal" lifestyle, which will have a profound impact not only on communicable diseases but also on noncommunicable diseases, including hypertension. Summarizing what is known and what requires further investigation in this field may help to address the challenges we face. In the present review, we critically evaluate the existing evidence for the epidemiological association between COVID-19 and hypertension. We also summarize the current knowledge regarding the pathophysiology of SARS-CoV-2 infection with an emphasis on ACE2, the cardiovascular system, and the kidney. Finally, we review evidence on the use of antihypertensive medication, namely, ACE inhibitors and angiotensin receptor blockers, in patients with COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.